<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Upper gastrointestinal <z:hpo ids='HP_0002664'>neoplasia</z:hpo> in the esophagus, stomach, and pancreas is associated with the formation of preneoplastic <z:mpath ids='MPATH_160'>metaplasias</z:mpath> </plain></SENT>
<SENT sid="1" pm="."><plain>We have previously reported the up-regulation of human epididymis protein 4 (HE4) in <z:hpo ids='HP_0000001'>all</z:hpo> <z:mpath ids='MPATH_160'>metaplasias</z:mpath> in the stomach of humans and mice </plain></SENT>
<SENT sid="2" pm="."><plain>We have now sought to evaluate the expression of HE4 in <z:mpath ids='MPATH_160'>metaplasias</z:mpath>/preneoplastic precursors and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> of the human stomach, pancreas, and esophagus </plain></SENT>
<SENT sid="3" pm="."><plain>Tissue microarrays for <z:hpo ids='HP_0012126'>gastric cancers</z:hpo>, <z:hpo ids='HP_0002894'>pancreatic cancers</z:hpo>, and esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> were stained with antibodies against HE4 </plain></SENT>
<SENT sid="4" pm="."><plain>Immunostaining was quantified by digital imaging, and the results were evaluated to assess the expression in <z:mpath ids='MPATH_160'>metaplasias</z:mpath>, the expression in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> pathological subtypes, and the effects of expression on survival in patients with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>In patients with <z:hpo ids='HP_0012126'>gastric cancer</z:hpo> from Korea, HE4 was detected in 74% of intestinal and 90% of diffuse <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, whereas in a <z:hpo ids='HP_0012126'>gastric cancer</z:hpo> cohort from Johns Hopkins, HE4 was detected in 74% of intestinal-type and 92% of diffuse <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Nevertheless, in both cohorts, there was no impact of HE4 expression on overall survival </plain></SENT>
<SENT sid="7" pm="."><plain>In the esophagus, we observed the expression of HE4 in scattered <z:chebi fb="32" ids="24621">endocrine</z:chebi> cells within <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> samples, but Barrett columnar <z:mpath ids='MPATH_160'>metaplasias</z:mpath> and HE4 were detected in only 2% of esophageal <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>Finally, in the pancreas, HE4 expression was not observed in pancreatic intraepithelial <z:hpo ids='HP_0002664'>neoplasia</z:hpo> lesions, but 46.8% of <z:hpo ids='HP_0006725'>pancreatic adenocarcinomas</z:hpo> expressed HE4 </plain></SENT>
<SENT sid="9" pm="."><plain>Still, we did not observe any influence of HE4 expression on survival </plain></SENT>
<SENT sid="10" pm="."><plain>The results suggest that HE4 is up-regulated during gastric and pancreatic <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> </plain></SENT>
</text></document>